Published in Gene Therapy Weekly, December 27th, 2001
Approval by the EMEA will allow unified labeling for ET-743 for this indication throughout all member states of the European Union.
ET-743 is the first of a new class of antitumor agents that block the activation of genes in a unique way. ET-743 has multiple effects, such as selective inhibition of expression of key genes (including oncogenes) involved in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.